rs4235308 — PPARGC1A

Intronic variant in the PGC-1alpha gene linked to population-specific type 2 diabetes risk and mitochondrial biogenesis regulation

See your personal result for PPARGC1A

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

A Regulatory Switch in the Master of Mitochondrial Biogenesis

PPARGC1A encodes PGC-1alpha11 PGC-1alpha
peroxisome proliferator-activated receptor gamma coactivator 1-alpha, the master transcriptional coactivator controlling mitochondrial biogenesis and oxidative metabolism, sometimes called "the switch that turns on the power station." Every endurance adaptation your muscles make to training — more mitochondria, better fat oxidation, higher aerobic capacity — runs through PGC-1alpha. rs4235308 is an intronic variant in this gene that appears to influence gene expression and metabolic risk, though in ways that vary across populations.

The Mechanism

Located in intron 4 of PPARGC1A at chromosomal position 4:23,862,789 (GRCh38), rs4235308 is a T>C substitution on the plus strand. Because PPARGC1A sits on the minus strand, this corresponds to an A>G change on the coding strand. As an intronic variant, rs4235308 does not alter the PGC-1alpha protein sequence directly. Instead, it likely acts through regulatory mechanisms22 regulatory mechanisms
intronic variants can affect mRNA splicing, enhance transcription factor binding, or alter chromatin accessibility, all of which can change how much PGC-1alpha protein a cell produces. The C allele is moderately common globally (~40%), occurring at similar frequencies across most ancestral populations.

PGC-1alpha's role as a master regulator means even modest changes in its expression have downstream consequences: lower PGC-1alpha levels impair mitochondrial biogenesis, reduce the capacity for fat oxidation during exercise, and compromise the metabolic adaptations that normally follow endurance training. Whether rs4235308 alters PGC-1alpha expression in a meaningful way has not been directly demonstrated in functional studies.

The Evidence

The primary published data for rs4235308 comes from a 2015 study in African-origin populations33 2015 study in African-origin populations
Cheema et al. Genetic Associations of PPARGC1A with Type 2 Diabetes: Differences among Populations with African Origins. J Diabetes Res, 2015. Examining 110 Haitian American and 124 African American participants with and without type 2 diabetes, the researchers found striking population-specific effects: rs4235308 was associated with lower T2D risk in Haitian Americans (OR 0.42, P = 0.026) but higher T2D risk in African Americans (OR 2.53, P = 0.028). This reversal of direction — protective in one group, harmful in another — is characteristic of a variant in linkage disequilibrium44 linkage disequilibrium
LD, where a variant is statistically co-inherited with another nearby variant that is the true causal site; different LD patterns in different ancestral populations can make the same rs-number appear beneficial in one group and harmful in another with different causal variants in different populations. The study's small sample sizes (around 110 per population) mean these findings require replication.

The broader context for this variant comes from PPARGC1A biology. The gene's functional importance to exercise adaptation is well-established through its other variants: the Gly482Ser substitution at rs8192678 (a missense change in the same gene) predicts blunted improvements in aerobic fitness and insulin sensitivity after training, with carriers of the Ser allele showing only +11% vs +120% improvement in individual anaerobic threshold after a 9-month lifestyle intervention Stefan et al. 200755 Stefan et al. 2007. That rs4235308 sits in the same gene and tags similar metabolic outcomes is biologically coherent, even without direct mechanistic proof for this specific intronic site.

Practical Actions

Given the intronic location and emerging evidence, the most actionable implications of rs4235308 relate to what we know about PPARGC1A function generally: supporting mitochondrial biogenesis through targeted supplementation and high-intensity aerobic training can partially compensate for lower baseline PGC-1alpha activity. Coenzyme Q1066 Coenzyme Q10
an essential component of the mitochondrial electron transport chain; the ubiquinol form is better absorbed than ubiquinone in the ubiquinol form supports mitochondrial function directly. Zone 2 aerobic training — sustained effort at 60-70% of maximum heart rate — is among the strongest known stimuli for PGC-1alpha expression, making training structure an important lever for those with regulatory variants in this pathway.

The population-specific T2D associations reinforce that metabolic monitoring (fasting glucose, HbA1c) is warranted, particularly if family history of T2D is present.

Interactions

rs4235308 resides in the same gene as rs8192678 (Gly482Ser), the better-characterized PPARGC1A variant. They represent different types of variation in the same master regulator: rs8192678 alters the PGC-1alpha protein directly, while rs4235308 may affect expression levels. Carriers of risk alleles at both loci could face compounded impairment of mitochondrial biogenesis, though no published study has examined this specific combination.

PPARD (rs2016520, rs2267668) encodes PPARδ, a nuclear receptor that physically interacts with PGC-1alpha to drive mitochondrial gene expression. The Stefan et al. study demonstrated additive effects of PPARD and PPARGC1A Gly482Ser variants on training response, making PPARD variants natural interaction candidates for any PPARGC1A regulatory variant.

Nutrient Interactions

coenzyme Q10 increased_need

Genotype Interpretations

What each possible genotype means for this variant.

TT Normal

Common PPARGC1A genotype with normal mitochondrial regulation potential

The TT genotype at rs4235308 represents the reference allele combination. The limited published evidence (Cheema et al. 2015) found that in Haitian Americans, carrying the T allele was protective against type 2 diabetes relative to the C allele. The mechanism is indirect — this is an intronic variant, so any effects on PGC-1alpha are likely through expression rather than protein structure. Aerobic fitness potential, mitochondrial biogenesis capacity, and training response are predominantly shaped by other PPARGC1A variants (especially rs8192678) and by training habits, diet, and overall metabolic health.

CT Intermediate

One copy of the C allele — intermediate metabolic risk profile

As a heterozygous TC carrier, you have one copy of the C allele that population data associates with altered T2D risk. The intronic location suggests the mechanism involves PPARGC1A expression regulation rather than protein function. The published evidence is limited to one small study (Cheema et al. 2015, ~120 participants per group), so the magnitude of any effect is uncertain. The C allele frequency is similar across ancestry groups (~37-45%), so this is not a rare high-penetrance variant. Monitoring metabolic health markers and supporting mitochondrial function through evidence-based strategies is the practical take-away.

CC High Risk

Two copies of the C allele — elevated metabolic risk requiring active mitochondrial support

As a CC homozygote, you carry two copies of the allele associated with elevated T2D risk in African Americans in the Cheema et al. study (PMID 25977930). The intronic location of this variant means the mechanism is likely regulatory — altered PPARGC1A expression rather than a change in PGC-1alpha protein structure. Lower PPARGC1A expression would be expected to reduce mitochondrial biogenesis capacity, impair aerobic training adaptations, and predispose to insulin resistance — all of which increase T2D risk.

The evidence base is limited: one study, ~120 participants per ethnic group, no replication. The protective effect seen in Haitian Americans (OR 0.42) versus risk in African Americans (OR 2.53) suggests the true causal variant nearby differs across populations — a common pattern for intronic regulatory SNPs. The CC dosage at this locus is still an actionable signal, particularly in the context of a family history of T2D or metabolic syndrome.

Direct support of mitochondrial function through targeted supplementation and structured aerobic training is the most evidence-anchored strategy for PPARGC1A regulatory variant carriers, based on the established biology of PGC-1alpha and its role in metabolic health.